Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF Monotherapy vs ETV + TAF in HBV-HCC Immunotherapy
NCT07253220Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial in hepatocellular carcinoma (HCC) and hepatitis B (HBV) comparing TAF Monotherapy with ETV + TAF Combination (2 arms). Primary endpoint: Overall Survival at 24 months. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
entecavirtenofovir alafenamide
03
Conditions
hepatocellular carcinoma (HCC)hepatitis B (HBV)
Beyond the preview
Go deeper on NCT07253220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07253220.